Immunovant Inc

+0.10 (+0.90%)
Earnings Announcements

Immunovant Posts Quarterly Loss Per Share $0.29

Published: 06/01/2021 13:14 GMT
Immunovant Inc (IMVT) - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021.
Quarterly Loss per Share $0.29.
Plans to Resume Clinical Development of Imvt-1401 in Myasthenia Gravis (mg) and Warm Autoimmune Hemolytic Anemia (waiha).
Plans to Initiate Two Additional Mid-to-late Stage Studies in Next Year.
Cash Balance of Approximately $400 Million As of March 31, 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.